PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Paul B.J. Burton and Theresa A. Deisher

Serial No.: 10/646,308 Group Art Unit No.: 1646

Filed: August 21, 2003 Examiner: Jiang, Dong

For: COMPOSITIONS AND METHODS FOR TREATING

CARDIOVASCULAR DISEASE

Confirmation No.: 9578

Docket No.: 3432-US-NP

INFORMATION DISCLOSURE STATEMENT **BEFORE** MAILING DATE OF EITHER A FINAL ACTION OR NOTICE OF ALLOWANCE (37 CFR 1.97(c))

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure, applicant(s) submit(s) a "List of References Cited by Applicant" on a modified PTO-1449 form and provide(s) a copy of each of the listed references for consideration by the Examiner.

Applicants make no determination of relevancy with respect to the reference(s) submitted herewith and request the Examiner to make an independent determination of relevance and/or materiality of the reference(s).

Applicants have not cited nor provided two of the references cited in the European Search Report. The reference to Seko Yoshinori et al. has been previously provided and cited in this application in an IDS Statement and Form 1449 (Sept. 20, 2004). Cheung et al. was not cited nor provided because the publication date of this reference was July 2007, a number of years after the filing date of the first provisional application to which this application claims priority.

This Information Disclosure Statement is being filed after three months of the filing date of this national application or the date of entry of the national stage as set forth in § 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last, but before the mailing date of either: (1) a final action under § 1.113 or (2) a notice of allowance under § 1.311, whichever occurs first.

CERTIFICATE OF ELECTRONIC TRANSMISSION

I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is being electronically transmitted to Mail Stop Amendment, Commissioner of Patents, P.O., Box 1450, Alexandria, VA 22313-1450 on the date indicated below.

Date: August 18, 2010

Accompanying this transmittal is the fee set forth in 37 CFR 1.17(p) for submission of an information disclosure statement under § 1.97(c). (\$180.00). **Fee is being paid via EFS-Web.**

Applicant(s) request(s) consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Deposit Account No. 09-0089.

Respectfully submitted,

Christine M. Bellas

Attorney/Agent for Applicant(s)

Pristine Bellia

Registration No.: 34,122 Phone: (206) 265-8294 Date: August 18, 2010

Please send all future correspondence to:

22932

Amgen Inc. Law Department 1201 Amgen Court West Seattle, WA 98119-3105 (206) 265-7000